This study examines a new treatment called SC291 for people with certain types of blood cancer, specifically non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL). The treatment is given through a vein (called intravenously or IV) after a specific kind of chemotherapy. The study is divided into two parts: the first part is to find the right dose, and the second part is to see how safe and effective it is at that dose. Participants must have tried at least two treatments already. The study is open to adults aged 18-80, who have a decent health status and a life expectancy of at least 12 weeks. However, those who have had certain previous treatments or have specific health issues, like active autoimmune diseases or certain heart conditions, are not eligible.

• This is a Phase 1 trial, meaning it's an early study to find out if SC291 is safe.
• The study requires multiple visits for treatment and monitoring.
• Participants must have tried at least two previous treatments for their cancer.